• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- ​​​​​​​Tpoxx found to be well-tolerated, safe in US monkeypox patients

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/news-per...-be-well-tolerated-safe-us-monkeypox-patients

Tpoxx found to be well-tolerated, safe in US monkeypox patients


Filed Under:
Monkeypox
Stephanie Soucheray | News Reporter | CIDRAP News

Sep 09, 2022

Today in Morbidity and Mortality Weekly Report, researchers from the Centers for Disease Control and Prevention (CDC) provided data on safety outcomes on 369 patients who receiving the monkeypox antiviral drug tecovirimat (Tpoxx), noting that few adverse events were reported.

In related news, a study spotlighted neurologic complications such as encephalitis and seizures in monkeypox patients, Los Angeles County is investigating the death of an infected person, and federal officials are considering widening the vaccine pool to include people with HIV.

Side effects in 3.5% of Tpoxx users


Tpoxx was developed and tested for treating smallpox, but it is currently widely used in the United States to treat monkeypox patients under a Food and Drug Administration Expanded Access Investigational New Drug (EA-IND) ruling.

Of the 369 patients in today's study who were administered Tpoxx orally, adverse events were reported in 3.5% of patient, with only one adverse event classified as serious.

Roughly half of those administered the drug had HIV, and the median interval from initiation of tecovirimat to subjective improvement was 3 days and did not differ by HIV infection status, the authors said. Tecovirimat was taken for a prescribed 14-day regimen.

"Although this report could not evaluate efficacy, clinicians are encouraged to continue following CDC guidelines for tecovirimat use in patients with severe disease or at risk for severe disease," the authors said.

Tpoxx recipients were 97.7% male, with a median age of 36.5 years. Among patients with available data, 38.8% were reported to be non-Hispanic White, 34.7% were Hispanic or Latino, and 17.9% were non-Hispanic Black or African American.

The CDC reported 230 more monkeypox cases yesterday, raising the total to 21,504.

Monkeypox tied to neurologic complications


New research from the University College London (UCL) shows some monkeypox patients develop significant neurological complications, including encephalitis (brain inflammation), seizures, and confusion. The study was published in eClinicalMedicine yesterday.

The meta-analysis combed 19 cohort studies that included a total of 1,512 monkeypox patients. The investigators found that 2.7% patients experienced seizures (95% confidence interval [CI], 0.7% to 10.2%), confusion 2.4% (95% CI, 1.1% to 5.2%), and encephalitis 2.0% (95% CI, 0.5% to 8.2%). The patients were seen in outbreaks in the United States, Nigeria, Democratic Republic of the Congo, Republic of Congo, and the United Kingdom.

The study findings include patient data from previous outbreaks and a mix of virus clades, the authors warned.

In a press release, senior author Jonathan Rogers, MB BChir, of UCL, said, "We found that severe neurological complications such as encephalitis and seizures, while rare, have been seen in enough monkeypox cases to warrant concern, so our study highlights a need for further investigation."

Los Angeles investigating monkeypox death


Los Angeles County is investigating a death in a monkeypox patient, which would be the second such US case. Texas reported the death of a monkeypox patient in Harris County earlier this month, and officials in both cases are investigating what role monkeypox played in the fatalities.

In other US news, the Associated Press is reporting the White House is considering recommending monkeypox vaccination to all men with HIV and those recently diagnosed as having other sexually transmitted infections (STIs).

The recommendation may change, as a recent CDC study found 38% of those with monkeypox infections had been diagnosed with HIV, and 41% of monkeypox patients had been diagnosed with an STI. Worldwide, 44.9% of monkeypox patients with known HIV status are positive.

The CDC now recommends vaccination for close contacts and men who have sex with men (multiple partners) in an area with high visual spread.

Globally, the World Health Organization said in a new epidemiologic report that there have been 18 deaths globally in the current outbreak.
 
Back
Top Bottom